collection
MENU ▼
Read by QxMD icon Read
search

Gout

shared collection
13 papers 0 to 25 followers
https://www.readbyqxmd.com/read/26288657/characteristics-of-the-first-metatarsophalangeal-joint-in-gout-and-asymptomatic-hyperuricaemia-a-cross-sectional-observational-study
#1
Sarah Stewart, Nicola Dalbeth, Alain C Vandal, Keith Rome
BACKGROUND: This study aimed to identify patient-reported outcomes and clinician-assessed characteristics of the first metatarsophalangeal joint (1MTPJ) in people with gout and with asymptomatic hyperuricaemia by comparing them to normouricaemic controls. METHODS: Twenty four people with gout (without current symptoms of acute arthritis), 29 with asymptomatic hyperuricaemia and 34 age- and sex-matched controls participated in this cross-sectional observational study...
2015: Journal of Foot and Ankle Research
https://www.readbyqxmd.com/read/25876828/pharmacogenetic-considerations-in-the-treatment-of-gout
#2
REVIEW
Rebecca L Roberts, Lisa K Stamp
Gout is one of the most common forms of arthritis and the prevalence is increasing. Management comprises rapid and effective control of the inflammation in acute gout and sustained urate lowering in the long term. Improving the outcomes for cheaper old drugs and for the increasing number of new, more expensive agents is an important clinical goal. The role of pharmacogenetics in predicting response and adverse events to gout therapies is of considerable interest. Currently, prospective screening is employed to detect HLA-B*5801 carriage and glucose-6-phosphate dehydrogenase deficiency, to minimize occurrence of allopurinol hypersensitivity and pegloticase-related hemolytic anemia...
2015: Pharmacogenomics
https://www.readbyqxmd.com/read/25556668/febuxostat-for-the-treatment-of-gout
#3
REVIEW
Mary Barna Bridgeman, Benjamin Chavez
INTRODUCTION: Gout is a rheumatologic condition associated with elevated serum uric acid levels and deposition of monosodium urate crystals in joints and soft tissues. The xanthine oxidase inhibitor, allopurinol, has historically been the principle agent utilized for reducing elevated uric acid levels and treating underlying cause of gout symptoms; the availability of febuxostat, a newer non-purine selective xanthine oxidase inhibitor, represents an alternative therapy for those patients with contraindications or intolerance to allopurinol...
February 2015: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/25547991/advances-in-pharmacotherapy-for-the-treatment-of-gout
#4
REVIEW
Philip C Robinson, Nicola Dalbeth
INTRODUCTION: Gout is a common inflammatory arthritis affecting almost 6% of US males and 2% of US females. The central cause of gout is deposition of monosodium urate crystals, and the focus of treatment is aimed at crystal dissolution using urate-lowering therapy. AREAS COVERED: The review describes the current treatments for urate-lowering therapy including allopurinol, febuxostat, probenecid, benzbromarone and pegloticase. Anti-inflammatory treatment of acute flares and prophylaxis of flares with NSAIDs, colchicine, corticosteroids and anti-IL-1 agents is also reviewed...
March 2015: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/25151572/mechanism-of-action-of-colchicine-in-the-treatment-of-gout
#5
REVIEW
Nicola Dalbeth, Thomas J Lauterio, Henry R Wolfe
PURPOSE: The aims of this article were to systematically review the literature about the mechanism of action of colchicine in the multimodal pathology of acute inflammation associated with gout and to consider the clinical utility of colchicine in other chronic inflammatory diseases. METHODS: The English-language literature on PubMed was searched for articles published between 1990 and October 2013, with a cross-reference to citations across all years. Relevant articles pertaining to the mechanism of action of colchicine and the clinical applications of colchicine in gout and other inflammatory conditions were identified and reviewed...
October 1, 2014: Clinical Therapeutics
https://www.readbyqxmd.com/read/24650777/treatment-of-acute-gout-a-systematic-review
#6
REVIEW
Puja P Khanna, Heather S Gladue, Manjit K Singh, John D FitzGerald, Sangmee Bae, Shraddha Prakash, Marian Kaldas, Maneesh Gogia, Veronica Berrocal, Whitney Townsend, Robert Terkeltaub, Dinesh Khanna
OBJECTIVE: Acute gout is traditionally treated with NSAIDs, corticosteroids, and colchicine; however, subjects have multiple comorbidities that limit the use of some conventional therapies. We systematically reviewed the published data on the pharmacologic and non-pharmacologic agents used for the treatment of acute gouty arthritis. METHODS: A systematic search was performed using PubMed and Cochrane database through May 2013. We included only randomized controlled trials (RCTs) that included NSAIDs, corticosteroids, colchicine, adrenocorticotropic hormone (ACTH), interleukin-1 (IL-1) inhibitors, topical ice, or herbal supplements...
August 2014: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/24614592/optimizing-current-treatment-of-gout
#7
REVIEW
Frances Rees, Michelle Hui, Michael Doherty
Gout is the most common inflammatory arthritis worldwide. Although effective treatments exist to eliminate sodium urate crystals and to 'cure' the disease, the management of gout is often suboptimal. This article reviews available treatments, recommended best practice and barriers to effective care, and how these barriers might be overcome. To optimize the management of gout, health professionals need to know not only how to treat acute attacks but also how to up-titrate urate-lowering therapy against a specific target level of serum uric acid that is below the saturation point for crystal formation...
May 2014: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/23104464/evaluation-and-treatment-of-gout-as-a-chronic-disease
#8
REVIEW
Fernando Perez-Ruiz, Ana Maria Herrero-Beites
Gout is a disease caused by deposition of monosodium urate crystals in tissues. One of the limitations for successful treatment of gout is to consider it as an intermittent disease rather than a chronic inflammatory disease which, if improperly treated, leads to chronic clinical manifestations. In addition, gout is linked to increased cardiovascular morbidity and mortality.Urate-lowering therapy comprises both nonpharmacologic and pharmacologic interventions, but most patients will need urate-lowering drugs to achieve target therapeutic serum urate levels...
November 2012: Advances in Therapy
https://www.readbyqxmd.com/read/21846852/efficacy-and-tolerability-of-pegloticase-for-the-treatment-of-chronic-gout-in-patients-refractory-to-conventional-treatment-two-randomized-controlled-trials
#9
RANDOMIZED CONTROLLED TRIAL
John S Sundy, Herbert S B Baraf, Robert A Yood, N Lawrence Edwards, Sergio R Gutierrez-Urena, Edward L Treadwell, Janitzia Vázquez-Mellado, William B White, Peter E Lipsky, Zeb Horowitz, William Huang, Allan N Maroli, Royce W Waltrip, Steven A Hamburger, Michael A Becker
CONTEXT: Patients with chronic disabling gout refractory to conventional urate-lowering therapy need timely treatment to control disease manifestations related to tissue urate crystal deposition. Pegloticase, monomethoxypoly(ethylene glycol)-conjugated mammalian recombinant uricase, was developed to fulfill this need. OBJECTIVE: To assess the efficacy and tolerability of pegloticase in managing refractory chronic gout. DESIGN, SETTING, AND PATIENTS: Two replicate, randomized, double-blind, placebo-controlled trials (C0405 and C0406) were conducted between June 2006 and October 2007 at 56 rheumatology practices in the United States, Canada, and Mexico in patients with severe gout, allopurinol intolerance or refractoriness, and serum uric acid concentration of 8...
August 17, 2011: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/21228059/frequency-and-risk-factors-of-gout-flares-in-a-large-population-based-cohort-of-incident-gout
#10
Dietrich Rothenbacher, Paola Primatesta, Alberto Ferreira, Lucía Cea-Soriano, Luis A García Rodríguez
OBJECTIVE: So far, few data are available to characterize the flare history of patients with gout. The objective of this study was to describe the frequency and risk factors of gout flares with special consideration of the comorbidity. METHODS: A cohort study was conducted in a U.K. general practice database (The Health Improvement Network) including all patients aged 20-89 years diagnosed with incident gout between the years 2000 and 2007. RESULTS: In this study, 23 857 incident gout patients (mean age 61...
May 2011: Rheumatology
https://www.readbyqxmd.com/read/20370912/the-urate-lowering-efficacy-and-safety-of-febuxostat-in-the-treatment-of-the-hyperuricemia-of-gout-the-confirms-trial
#11
RANDOMIZED CONTROLLED TRIAL
Michael A Becker, H Ralph Schumacher, Luis R Espinoza, Alvin F Wells, Patricia MacDonald, Eric Lloyd, Christopher Lademacher
INTRODUCTION: The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8.0 mg/dL in a six-month trial. METHODS: Subjects (n = 2,269) were randomized to febuxostat 40 mg or 80 mg, or allopurinol 300 mg (200 mg in moderate renal impairment). Endpoints included the proportion of all subjects with sUA <6.0 mg/dL and the proportion of subjects with mild/moderate renal impairment and sUA <6...
2010: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/19664185/gout-novel-therapies-for-treatment-of-gout-and-hyperuricemia
#12
REVIEW
Robert Terkeltaub
In the past few decades, gout has increased not only in prevalence, but also in clinical complexity, the latter accentuated in part by a dearth of novel advances in treatments for hyperuricemia and gouty arthritis. Fortunately, recent research reviewed here, much of it founded on elegant translational studies of the past decade, highlights how gout can be better managed with cost-effective, well-established therapies. In addition, the advent of both new urate-lowering and anti-inflammatory drugs, also reviewed here, promises for improved management of refractory gout, including in subjects with co-morbidities such as chronic kidney disease...
2009: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/17276548/comparison-of-oral-prednisolone-paracetamol-and-oral-indomethacin-paracetamol-combination-therapy-in-the-treatment-of-acute-goutlike-arthritis-a-double-blind-randomized-controlled-trial
#13
RANDOMIZED CONTROLLED TRIAL
Chi Yin Man, Ian T F Cheung, Peter A Cameron, Timothy H Rainer
STUDY OBJECTIVE: We compare the analgesic efficacy and adverse effects of oral prednisolone/acetaminophen and oral indomethacin/acetaminophen combination therapy in the treatment of acute goutlike arthritis in patients presenting to an emergency department (ED). METHODS: This is a double-blind, randomized, controlled study in a university hospital emergency department (ED) in the New Territories of Hong Kong. Patients older than 17 years and presenting between February 1, 2003, and June 30, 2004, with a clinical diagnosis of goutlike arthritis were randomized to receive either oral prednisolone/acetaminophen or oral indomethacin/acetaminophen combination therapy...
May 2007: Annals of Emergency Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"